Congenital polycythemias/erythrocytoses

Haematologica

Volumn 90, Issue 1, 2005, Pages 109-116

  Gordeuk, Victor R ^a   Stockton, David W ^b   Prchal, Josef T ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ataxia telangectasia; Polycythemia; Von Hippel Landau gene

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN;

ALLELE; ARTERY THROMBOSIS; CANCER INCIDENCE; CYANOTIC HEART DISEASE; EPOR GENE; ERYTHROCYTE; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; FAMILIAL DISEASE; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GERM LINE; GERM LINE MUTATION; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HYPOXIA; LUNG DISEASE; METHEMOGLOBINEMIA; MOLECULAR BIOLOGY; MORTALITY; OXYGEN AFFINITY; OXYGEN SENSING; OXYGEN TISSUE LEVEL; PHLEBOTOMY; POLYCYTHEMIA; RARE DISEASE; REVIEW; SURVIVAL; VHL GENE;

HOMEOSTASIS; HOMOZYGOTE; HUMANS; OXYGEN; POINT MUTATION; POLYCYTHEMIA; RUSSIA; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 13244275298     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-90.
2. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003;102:3793-6.
3. Semenza GL. Hypoxia-inducible factor 1. Control of oxygen homeostasis in health and disease. Fed Res 2001;49: 614-7.
4. Wane GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-heiix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-4.
5. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1a protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 1995;97:4748-53.
6. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447.
7. Jaakola P, Mole DR, Tian YM, Wilson MI, Bielbert J, Gaskell SJ, et al. Targeting of HIF-α to the von Hippel Lindau ubiquitylation complex by O2-regulated hydroxylation. Science 2001; 292:48-72.
8. Ivan M, Kongo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
9. Polyakova LA. Familial erythrocytosis among inhabitants of the Chuvash ASSR. Probl Gematol 1974;10:30-6.
10. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia, Blood 1997;89:2148-54.
11. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen-sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. 2004; 103:3924-32.
12. Ang SO, Chen H, Gordeuk VR, Polyakova LA, Miasnikova GY, Kralovics R, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cell Mol Dis 2002;28:57-62.
13. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-21.
14. Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. Human hematopoietic progenitors express erythropoietin. Blood 1998;91:3766-72.
15. Sato T, Maekawa T, Watanabe S, Tsuji K, Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 1998;106:263-70.
16. Liu E, Pastore YD, Divorky V, Ponka P, Semenza GL, Prchal JT. Defective erythropoiesis in HIF-1α-null mouse embryos. ISEH 2004;32:52.
17. Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101:1591-5.
18. Percy MJ, McMullin MF, Jowitt SN, Potter M, Treacy M, Watson WH, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood 2003;102: 1097-9.
19. Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003;73:412-9.
20. Cario H, Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider DT, et al. Mutations in the von-Hippel-Lindau (vHL) tumor suppressor gene and vHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005;90:19-24.
21. Bento MC, Chang KT, Guan YL, Liu EL, Pastore Y, Ribeiro MKL, et al. Five new Caucasian patients with congenital Polycythemia due to heterogenous VHL gene mutations. Haematologica 2005;2005;90:128-9.
22. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294-301.
23. Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW, et al. The worldwide distribution of the VHL 598C->T mutation indicates a single founding event. Blood 2004;103:1937-40.
24. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HEP-2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21: 3995-4004.
25. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111:600-2.
26. Van Wijk MJ, Kublickiene K, Boer K, Van Bavel E. Vascular function in preeclampsia. Cardiovasc Res 2000;47: 38-48.
27. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003; 112:645-57.
28. Maran J, Jedlickova K, Stockton D, Prchal JT. Finding the novel molecular defect in a family with high erythropoietin autosomal dominant polycythemia. Blood 2003;102:[Abstract #4359].
29. Perrine GM, Prchal JT, Prchal JF. Study of a polycythemic family. Blood 1977; 50:134.
30. Prchal JT, Crist WM, Goldwasser E, Perrine G, Prchal JF. Autosomal dominant polycythemia. Blood 1985;66: 1208-14.
31. Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis causes by increased sensitivity to erythropoietin. Blood 1991;78:3066-9.
32. Emanuel PD, Eaves CJ, Broudy VC, Moore MR, D'Andrea AD, Prchal JF, et al. Hereditary polycythemia in three unrelated families. Blood 1992;79: 3019-31.
33. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol 2001;38:10-20.
34. Queisser W, ME Heim, JM Schmitz, Worst P. Idiopathic familial erythrocytosis. Report on a family with autosomal dominant inheritance. Dtsch Med Wochenschr 1988;113:851-6.
35. Prchal JT, Prchal JE, Semenza GL, Sokol L. Familial polycythemia. Science 1995; 268:1831-2.
36. Sokol L, Kralovics R, Hubbell GL, Prchal JT. A novel erythropoietin receptor mutation associated with primary familial polycythemia and severe cardiovascular and peripheral vascular disease. Blood 2001;98: [abstract #937].
37. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF. The cytoplasmic region of the erythropoietin receptor contains non-overlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11:1980-7.
38. Winkelmann JC, Penny, LA, Deaven LL, Forget, BG, Jenkins RB. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood 1990;76:24-30.
39. Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA 2001;98: 986-91.
40. Zang H, Sato K, Nakajima H, McKay C, Ney PA, Ihle JN. The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J 2001;20:3156-66.
41. Kralovics R, JT Prchal. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001;68:115-21.
42. Jedlickova K, Stockton DW, Prchal JT. Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2. Blood Cells Mol Dis 2003;31: 327-31.
43. Lichtman MA, Murphy MS, Adamson JW. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique. Ann Intern Med 1976;84:517-20
44. Andreasson B, Carneskog J, Lindstedt G, Lundberg PA, Swolin B, Wadenvik H, et al. Plasma erythropoietin concentrations in polycythaemia vera with special reference to myelosuppressive therapy. Leuk Lymphoma 2000;37: 189-95.
45. Glicklich D, Burris L, Urban A, Tellis V, Greenstein S, Schechner R, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001;12:1958-64.
46. Arcasoy MO, Karayal AF, Segal HM, Sinning JG, Forget BG. A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood 2002;99:3066-9.
47. Kralovics R, Sokol L, Prchal JT Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Invest 1998;102:124-9.
48. Haga P, Cotes PM, Till JA, Minty BD, Shineboume EA. Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease. Blood 1987;170:822-6.